Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lupus patients: two experimental drugs show promise in reducing disease activity

NCT ID NCT03656562

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two experimental drugs, VAY736 and CFZ533, in 107 adults with systemic lupus erythematosus (SLE). The goal was to see if these drugs could reduce lupus symptoms and allow patients to lower their steroid use. Participants received either one of the drugs or a placebo, and researchers measured disease activity and safety over several months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

  • Novartis Investigative Site

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510000, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210008, China

  • Novartis Investigative Site

    Shanghai, 200127, China

  • Novartis Investigative Site

    Prague, 128 00, Czechia

  • Novartis Investigative Site

    Pessac, 33604, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Berlin, 10117, Germany

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, 1023, Hungary

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4578510, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4600001, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104-8560, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 162-8655, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1608582, Japan

  • Novartis Investigative Site

    Bydgoszcz, 85-168, Poland

  • Novartis Investigative Site

    Poznan, 60-218, Poland

  • Novartis Investigative Site

    Warsaw, 00-874, Poland

  • Novartis Investigative Site

    Moscow, 115522, Russia

  • Novartis Investigative Site

    Saint Petersburg, 194044, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620144, Russia

  • Novartis Investigative Site

    Gwangju, 61469, South Korea

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    Taichung, Taiwan ROC, 40201, Taiwan

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Novartis Investigative Site

    Taichung, 407219, Taiwan

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.